Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2017 Dec 11;24(4):641–648. doi: 10.1016/j.bbmt.2017.12.774

Table 2.

Summary of studies reporting outcomes associated with MRD status

Study and reference Patient Population MRD methodology Outcome
GEM2000; Paiva et al.14 Day 100 post-ASCT MFC MRD negativity associated with improved PFS and OS
GEM2000/GEM2005; Paiva et al.15 Day 100 post-ASCT MFC MRD positivity associated with loss of CR status
MRC Myeloma IX; Rawstron et al.16 Day 100 post-ASCT MFC MRD negativity associated with improved PFS and OS
MRC Myeloma IX; de Tute et al.17 Post-induction MFC Impact of MRD negativity is independent of induction regimen
IFM 2009; Attal et al.3 Post-consolidation or post-maintenance MFC MRD negativity associated with improved PFS
IFM 2009; Avet-Loiseau et al.34 Post-maintenance NGS MRD negativity associated with improved 3-yr PFS
Chakraborty et al.18 Day 100 post-ASCT MFC MRD negativity associated with improved PFS and OS
GEM05>65y; Paiva et al.19 Post-induction, ASCT ineligible MFC MRD negativity associated with improved PFS
PETHEMA/GEM trials; Lahuerta et al.20 Nine months post-enrollment MFC MRD negativity associated with improved PFS and OS
Paiva et al.22 Relapsed/refractory MFC MRD negativity associated with improved TTP
POLLUX; Dimopoulos et al.23 Relapsed/refractory NGS MRD negativity associated with improved PFS
POLLUX/CASTOR; Avet-Loiseau et al.37 Relapsed/refractory NGS MRD negativity associated with fewer PFS events
EMN02/HO95; Oliva et al.24 Prior to maintenance MFC MRD negativity associated with improved 3-yr PFS